Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Evotec SEEVOTF 59 Debt-to-EBITDA is -0.81 as of Mar. 2026. GuruFocus rates EVOTF with a GF Score™ of 59/100 and a GF Value™ of $13.81. The stock has 5 warning signs investors should review. Among 690 Drug Manufacturers companies, Evotec SE ranks worse than 144927.39% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Evotec SE's Debt-to-EBITDA or its related term are showing as below:
EVOTF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -8.8 Med: 2.81 Max: 25.96
Current: -2.36
During the past 13 years, the highest Debt-to-EBITDA Ratio of Evotec SE was 25.96. The lowest was -8.80. And the median was 2.81.
EVOTF's Debt-to-EBITDA is ranked worse than 100% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.65
vs EVOTF: -2.36
Evotec SE (OTCPK:EVOTF) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Evotec SE Debt-to-EBITDA Related Terms
Evotec SE Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Evotec SE's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EVOTF vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Evotec SE's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Evotec SE (EVOTF) has a Debt-to-EBITDA of -0.81 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Evotec SE. According to the industry distribution chart, Evotec SE ranks #999999 out of 690 companies in the Drug Manufacturers industry.
Is Evotec SE's Debt-to-EBITDA too high?
Evotec SE's current Debt-to-EBITDA is -0.81. Based on the distribution chart, Evotec SE ranks #999999 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Evotec SE has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #999999 out of 690 companies for Debt-to-EBITDA. This places Evotec SE in the lower half of its industry. The industry median Debt-to-EBITDA is 1.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.65, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Evotec SE. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current Debt-to-EBITDA is -0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Evotec SE (EVOTF) has a current Debt-to-EBITDA of -0.81. The stock's GF Value™ is $13.81, compared to a current price of $6.69 — trading 51.6% below its estimated fair value. The current Debt-to-EBITDA is -0.81. Evotec SE's overall GF Score™ is 59/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Evotec SE (EVOTF), the current Debt-to-EBITDA is -0.81 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (EVOTF) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of $6.69 is trading 51.6% below its estimated GF Value™ of $13.81.
Key valuation signals for EVOTF:
Debt-to-EBITDA: -0.81
GF Value™: $13.81 vs. price of $6.69 (51.6% below fair value)
No single metric tells the full story. See the EVOTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
59GF Score
Get the complete analysis for EVOTF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVOTF has been successfully added to your 
